Background: Multidrug resistance (MDR) Pseudomonas aeruginosa has become a major clinical problem because of its resistance to a variety of antibiotic classes and the limited number of effective therapy options. Objectives: This study was to perform structure-based design, molecular docking and molecular characterization of Uridine-based and Liponucleoside derivatives of essential translocase in MDR P. aeruginosa (MraY). Results : An antimicrobial resistance profile of (44) forty-four isolates of P. aeruginosa revealed high levels of resistance to, cefotaxime, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole (100%), and 60% of strains were resistant to the carbapenems. All the clinical isolates were positive results in PCR for the presence of MraY gene, its conserved a widespread distribution, and therapeutic importance. Cavity detection and virtual screening in five possible binding pockets resulted in Cavity1 (C1) having a volume of 1819 Å3 at the coordinates (-20, -1, 14) being the main catalytic active site. The natural reference inhibitor Muraymycin C2 showed a high binding interaction of -9.6 kcal/mol within the C1, with significant interactions with the residue ASP115, ASP116, SER120 and THR73. While, the candidate ligand, Uridine 5ˈ-monophosphate, showed a stable and consistent binding score of (-7.6 kcal /mol) in C1, with supporting hydrogen bonds with ALA56, ASP116 and THR71.
ADMET and toxicological profiling indicated that Uridine 5ˈ-monophosphate possesses a favorable molecular weight (324.18 g/mol) and compliance with drug-like properties, while both evaluated ligands exhibited exceptionally clean safety profiles, showing no mutagenicity (AMES), hepatotoxicity, cardiotoxicity (hERG) or skin sensitization risks. Conclusions: The findings highlight that while Muraymycin C2 serves as a high-affinity natural benchmark, the uridine-based scaffold provides a non-toxic and chemically tractable framework for future lead optimization against MDR P. aeruginosa.
Keywords: Uridine 5ˈ-monophosphate, MraY translocase, Clinical isolates Multidrug-resistant Pseudomonas aeruginosa, ADMET profiling, Muraymycin C2, Structural-based drug design, Molecular docking.